Company aims to accelerate innovation, boost operational efficiency, and redefine pharma with AI-driven solutions.

Mankind Pharma, India’s fourth-largest pharmaceutical company, has announced a strategic partnership with OpenAI to embed artificial intelligence across its entire value chain. This collaboration positions Mankind among the first Indian pharma players to fully integrate advanced AI into core operations, with the goal of delivering faster innovation, sharper insights, and greater value for patients, doctors, and the broader healthcare ecosystem.

Through OpenAI Enterprise, Mankind Pharma will integrate GPT-powered solutions into multiple functions, including field force enablement, digital marketing, R&D, manufacturing, and medical affairs. The company aims to transform complex data into actionable intelligence, streamline communication, and drive operational excellence.

Arjun Juneja, Chief Operating Officer, Mankind Pharma, commented:

“Partnering with OpenAI is a pivotal step in building the pharma organization of the future. By embedding AI into our core operations, we’re enabling our teams to work faster, smarter, and with greater agility – whether in field force effectiveness, supply chain planning, or R&D acceleration. This is about more than automation; it’s about creating a responsive, intelligent, and future-ready enterprise. We are proud to lead this shift in Indian pharma and set new benchmarks for technology-driven growth.”

Key Focus Areas of Integration

• Smarter Decision-Making: GPT-powered dashboards delivering real-time, data-driven insights across R&D, supply chain, and commercial operations.
• Faster, Compliant Communication: Automated, multilingual content for healthcare professionals and patients, ensuring regulatory compliance with speed and accuracy.
• Function-Specific AI Agents: Custom AI agents to optimize Sales & Marketing, R&D, and HR efficiency.
• Advanced Clinical Intelligence: Streamlined literature reviews and real-time insights from clinical and genomic data to accelerate scientific discovery.
• Manufacturing Excellence: AI-powered analysis of batch records and sensor data for early anomaly detection and precise corrective action.

Since July 2025, Mankind Pharma has rolled out custom GPTs across its workforce, boosting the effectiveness of its Sales & Marketing teams, strengthening demand forecasting, enhancing procurement processes, and improving multilingual communications. Field force performance is now trackable in real time, while clinical research and manufacturing processes have become more proactive and predictive – allowing leadership to focus on strategic growth.

Custom GPTs enable organizations to build tailored AI assistants with defined tone, personality, and specialized knowledge, all while integrating proprietary data and workflows – without requiring deep technical expertise.

Oliver Jay, Managing Director, International at OpenAI, said:

“Mankind Pharma’s company-wide adoption of ChatGPT Enterprise shows the practical impact AI can have in highly regulated industries like pharmaceuticals. By responsibly deploying AI in research, operations, and medical communications, Mankind is improving efficiency and fueling innovation. We are excited to support them as they explore new, safe, and scalable applications of AI across the healthcare value chain.”